Legend Capital returned for the round that also featured a host of other insurance providers and Chinese state-owned entities such as Temasek.

China-based drug developer Innovent Biologics has raised $260m in a series D round that featured corporates such as Legend Capital, an investment arm of conglomerate Legend Holdings, China Money Network reported today.

Insurance providers China Life Investment Holding, Taikang Insurance and Ping An Insurance also participated in the round, which was led by an unnamed fund operated by China government-owned firm State Development and Investment Corporation (SDIC).

Temasek, the investment arm of the government of Singapore, and Hillhouse Capital also…